Caroline Seymour


Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC

November 25th 2020

Milind Javle, MD, provides insight into the current treatment paradigm of advanced HCC and the potential influence ongoing research regarding biomarkers of response and novel combinations could have on the field.

CAR T-Cell Therapy Creates Opportunities for Individualized Treatment in MCL

November 24th 2020

Alan P. Z. Skarbnik, MD, highlights how treatment decisions in mantle cell lymphoma have become more nuanced since the FDA approval of the CAR T-cell therapy brexucabtagene autoleucel in the relapsed/refractory setting.

Sotorasib Displays Disease Control, Safety in KRAS G12C–Mutant Gastrointestinal Cancers

November 22nd 2020

Sotorasib was well tolerated and led to disease control in the majority of patients with heavily pretreated KRAS G12C–mutant gastrointestinal malignancies.

Blood-Based Methylation Assay Enables Early, Accurate Detection of Solid Tumors

November 20th 2020

The noninvasive blood-based targeted methylation assay ELSA-seq identified early cancers with high specificity and provided accurate predictions of the tissue of origin.

Ruesch Center Symposium to Spotlight Advances, Applications in GI Cancers, Luminary Awards

November 17th 2020

November 17, 2020 — The 11th Annual Ruesch Center Symposium, taking place virtually on November 20 to 21, 2020, will feature sessions that span innovations in gastrointestinal cancer, advances in nuclear imaging and therapy for neuroendocrine tumors, precision oncology web educational resource, and patient symposia, bringing participants together in a forum for discussion, networking, and debate on pressing issues in the field.

Urelumab Induces Additive Benefit With Vaccine/Nivolumab Combo in Pancreatic Cancer

November 13th 2020

November 13, 2020 – The addition of urelumab, an anti-CD137 agonist to the GVAX vaccine and nivolumab led to a 30% pathologic response rate and was associated with mild toxicity as neoadjuvant or adjuvant therapy in patients with resectable pancreatic ductal adenocarcinoma.

Herpes Simplex-1 Oncolytic Showcases Antitumor Activity Across Heavily Pretreated Solid Tumors

November 13th 2020

November 13, 2020 - The genetically modified herpes simplex-1 oncolytic RP2 demonstrated encouraging clinical activity and an acceptable safety profile in heavily pretreated patients with advanced solid tumors

Cemiplimab Elicits Antitumor Activity in Metastatic Basal Cell Carcinoma

November 12th 2020

November 12, 2020 - Cemiplimab demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma after progression on or intolerance to hedgehog inhibitors

Leveraged Modalities are Leading to Improved Survival in EGFR+ NSCLC

November 11th 2020

November 11, 2020 - Rao Mushtaq, MD, provides perspective on these pivotal data in EGFR-mutant non–small cell lung cancer.

Treatment Selection in CLL Broadens Beyond Discussions of Efficacy

November 9th 2020

Alexey V. Danilov, MD, PhD, discusses BTK inhibitors and BCL-2 inhibitors that have led to a paradigm shift in the treatment of patients with chronic lymphocytic leukemia.